TL;DR — CagriSema (Cagrilintide + Semaglutide)
- What it is: A once-weekly fixed-dose combination of a long-acting amylin analog (cagrilintide 2.4 mg) and the GLP-1 receptor agonist semaglutide 2.4 mg.
- Primary mechanism: Dual hit on appetite — amylin receptors AMY1/AMY3 plus GLP-1 receptors converging on the hypothalamus, hindbrain, and septum.
- Who it’s for: Enhanced men and women who need to strip body fat without torching lean mass on a monohormone GLP-1.
- Key differentiator: REDEFINE 1 Phase 3a data — ~22.7% body weight reduction versus ~16.1% with semaglutide monotherapy at 68 weeks in on-treatment patients.
- Natural Plus angle: Low-dose pulsing stacked with protein-forward nutrition and resistance training — the opposite of “skinny fat on a pen.”
The Deep Biochemistry of CagriSema
Cagrilintide is a long-acting amylin analog engineered for once-weekly dosing. It binds amylin receptors AMY1 (calcitonin receptor + RAMP1) and AMY3 (CT + RAMP3), which are densely expressed in the area postrema of the hindbrain and in hypothalamic feeding circuits. Amylin is the pancreatic β-cell’s co-secreted partner to insulin, released in rough parity on every meal. Its physiological job: slow gastric emptying, suppress glucagon, and — most importantly for body composition — clamp down on food intake via brainstem circuitry.
Semaglutide is a GLP-1 receptor (GLP-1R) agonist. GLP-1 is an incretin secreted by intestinal L-cells. Its receptors cluster in the arcuate nucleus, nucleus tractus solitarius, and paraventricular nucleus. Downstream, GLP-1R activation raises cAMP, potentiates glucose-stimulated insulin secretion, suppresses glucagon, and — again — crushes hedonic feeding drive.
Here is the key insight: amylin and GLP-1 hit partially overlapping but mechanistically distinct appetite circuits. Amylin works through the brainstem “satiety relay,” while GLP-1 dominates hypothalamic hedonic appetite. Stack them and you get additive, not redundant, appetite suppression. The NEJM publication of REDEFINE 1 (NEJMoa2502081) showed estimated mean weight change at week 68 of −20.4% for CagriSema versus −3.0% for placebo. Among patients who stayed on-treatment, CagriSema hit −22.7%, semaglutide monotherapy −16.1%, and cagrilintide monotherapy −11.8% — a textbook additive curve. Roughly 60% of patients achieved ≥20% weight loss. Glucose, blood pressure, waist circumference, and lipid panels all improved concurrently, and 88% of prediabetics reverted to normoglycemia.
Tony Huge Laws of Biochemistry Physics Applied
CagriSema is a clean illustration of Law 5 of the Tony Huge Laws of Biochemistry Physics — Independent Receptor Stacking. The amylin receptor complex and the GLP-1 receptor are physically different proteins, coupled to different downstream signaling cascades, expressed on (partially) different neurons. Activating both in parallel gives additive appetite suppression without the diminishing returns you’d see from dose-escalating either one alone. Pushing semaglutide from 2.4 mg to 4.0 mg does not buy you another 10% body weight — the GLP-1R is already saturated and side effects climb. But adding a completely different receptor (amylin) unlocks a fresh signaling channel. Parallel batteries, not series.
The Natural Plus Protocol
The default clinical dose is 2.4 mg/2.4 mg weekly after titration, but that’s engineered for obesity phenotypes. Enhanced men who are already lean and simply cutting for a photoshoot or contest do not need the full injection-site-sore dose.
Tony’s approach: microdose CagriSema (roughly one-quarter to one-half of the label dose) pulsed weekly during a 8–16 week cutting phase, timed with aggressive resistance training and protein intake of 1 g per pound of lean mass per day. This retains muscle, blunts hedonic cravings, and pulls body fat without the “ozempic face” skeletonization that happens to sedentary people on full monotherapy doses. Cycle off for at least 4–6 weeks between pulses to prevent receptor desensitization and preserve endogenous amylin/GLP-1 tone.
Bloodwork to monitor: lipase and amylase (pancreatitis risk), HbA1c, fasting insulin, calcitonin (amylin analog safety marker), thyroid panel. Always run an injection-site rotation protocol and keep cycle support fundamentals — TUDCA, NAC, magnesium — dialed in.
Stacking Recommendations
| Stack Compound | Pathway | Why It Synergizes |
|---|---|---|
| MK-677 (Ibutamoren) | GHSR / GH-IGF-1 | Separate ghrelin receptor — protects lean mass during aggressive fat loss phase. |
| BPC-157 | GI repair / growth factor | Counters GI side effects of GLP-1 agonism; repairs gut lining stressed by slower emptying. |
| Retatrutide or Tirzepatide (alternate, not concurrent) | GLP-1 / GIP / glucagon | Rotation option for patients who plateau on CagriSema. |
| Testosterone / Enclomiphene | Androgen receptor | Lean mass retention on aggressive caloric deficit. |
Internal links: see the Enhanced Athlete Protocol peptides page, the MK-677 deep dive, the BPC-157 + TB-500 stack guide, and the Retatrutide triple agonist breakdown.
Who Should Use CagriSema?
This is not a beginner compound. The right candidate is a metabolically stalled Enhanced man or woman who has already exhausted aggressive nutrition (protein + fiber, low refined carb), built resistance training capacity, and still carries stubborn visceral or lower-body fat. It is particularly useful for patients over 35 with insulin resistance signatures on bloodwork — elevated fasting insulin, high triglyceride-to-HDL ratio, HbA1c trending up. It is wrong for lean competitors below 12% body fat looking for “the last little bit,” who will instead lose strength and muscle.
Timeline: What to Expect
| Timeframe | What to Expect |
|---|---|
| Week 1–2 | Noticeable appetite suppression. Mild nausea. Hydration becomes critical. |
| Week 4 | 3–5% body weight reduction. Visceral fat shrinks first. Cravings quiet down. |
| Week 8 | 8–12% body weight reduction on protocol dose. Waist circumference down 2–4 inches. |
| Week 12+ | 15–20% reduction possible. Strength may dip if protein and training fall off. Cycle off or titrate down. |
Interesting Perspectives: Beyond the Obvious
The dirty secret of the amylin half of this stack: amylin fibrils are the exact protein that aggregates into pancreatic islet amyloid in long-standing type 2 diabetes. Cagrilintide is a re-engineered amylin analog specifically designed to resist amyloid aggregation while retaining the receptor pharmacology — a quiet triumph of medicinal chemistry that gets zero marketing attention. A second underappreciated angle: emerging preclinical and rodent data suggest amylin agonism has direct neuroprotective effects in Alzheimer’s models, likely via improved brain insulin signaling and reduced amyloid-β aggregation. That means CagriSema may turn out to be a dual obesity-plus-neurodegeneration drug by the time Phase 3b cognition data is published. The third angle worth watching: hedonic versus homeostatic appetite control. CagriSema appears to suppress the hedonic “I’m bored, eat ice cream” drive more aggressively than pure semaglutide. This matters because food addiction is a neurological disease as much as a metabolic one — and we are now, for the first time, treating both ends simultaneously.
References
- Garvey WT, et al. “Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2025. NEJMoa2502081
- Kruse Hansen T, et al. “Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.” Current Obesity Reports, 2023. PMID: 36883831
- Larsen AT, et al. “Cagrilintide lowers body weight through brain amylin receptors 1 and 3.” Molecular Metabolism, 2025. PMC12270663
- Frias JP, et al. “Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.” The Lancet, 2023.
- Novo Nordisk. “REDEFINE 1 Phase 3a results presented at ADA 2025.” Pharmacy Times coverage. link
- Adams JM, et al. “Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons.” Diabetes, 2018.
Frequently Asked Questions
What is CagriSema?
CagriSema is a fixed-dose once-weekly combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). It targets two separate appetite-regulating pathways simultaneously.
What dose should I start on?
The label dose is 2.4 mg/2.4 mg weekly after slow titration. Tony’s enhanced approach is to microdose at one-quarter to one-half of label, cycled in 8–16 week pulses with at least 4 weeks off. Never jump straight to the full dose.
What are the side effects?
Nausea, reduced appetite (which is the point), occasional vomiting, constipation, injection-site tenderness. Rare: pancreatitis, gallbladder events. Monitor lipase, amylase, HbA1c, and calcitonin quarterly.
Can I stack CagriSema with testosterone or SARMs?
Yes, and you should if you want to hold lean mass. Testosterone, enclomiphene, or a mild SARM during a CagriSema cut protects muscle while body fat drops. Never run a GLP-1 agonist solo if you care about strength.
Who should NOT use CagriSema?
People with a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, severe gastroparesis, active pancreatitis, or pregnancy. Very lean competitive athletes under 12% body fat are also wrong candidates.
Related Reading
Cross-reference the Enhanced Athlete Protocol hub, the GLP-1 anti-aging stack, the tirzepatide vs semaglutide comparison, and the semaglutide microdosing for bodybuilders.